Skip to content

The Role of the Pulmonary Vasculature in the Fontan Circulation

The Role of the Pulmonary Vasculature in the Fontan Circulation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02414321
Enrollment
20
Registered
2015-04-10
Start date
2015-06-30
Completion date
2024-10-30
Last updated
2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease, Fontan Operation, Pulmonary Vascular Remodeling, Pulmonary Vascular Resistance

Brief summary

This study aims to explore the structural and functional characteristics of the pulmonary vasculature in adult Fontan patients. Objectives: * Determine the effect of pulmonary vasodilatation on indexed cardiac output during simulated exercise. * Characterization of structural properties of small pulmonary arteries.

Detailed description

Rationale: The Fontan circulation is a palliation for patients with a functionally univentricular heart. The Fontan circulation is characterized by impaired exercise capacity and gradual attrition over time. To date treatment options are extremely limited. It has been proposed that pulmonary vascular resistance (PVR) is the controlling and limiting factor of cardiac output in the Fontan circulation. Remodeling of the pulmonary vasculature and increasing PVR are possible key factors in the long term failure of the Fontan circulation. Optical Coherence Tomography (OCT) is an intravascular imaging modality used for structural characterization of blood vessels. Nitric oxide is a pulmonary vasodilator used in pulmonary vascular response tests, aimed at lowering PVR which may improve cardiac output in the Fontan circulation. These two diagnostic procedures are tools to study the structural and functional characteristics of the pulmonary vasculature in the Fontan circulation. The results of this study could identify the pulmonary circulation as a future treatment target in Fontan patients and may provide clues for new therapeutic treatment strategies to improve the long term outcome of these patients. Study procedure: The study protocol will be performed during a clinically indicated cardiac catheterization. In the context of this study additional measurements will be performed which will include a pulmonary vascular response test, trans-thoracic echocardiography and pulmonary artery OCT measurements.

Interventions

None listed

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Fontan group * written informed consent * Clinical indication for cardiac catheterization Control group * written informed consent * Clinical indication for right heart catheterization * Absence of pulmonary vascular disease * Normal pulmonary vascular hemodynamic profile

Exclusion criteria

Fontan group * Standard

Design outcomes

Primary

MeasureTime frameDescription
vasodilatationchange in indexed cardiac output between baseline and after 10 minutes of pulmonary vasodilatation at heart catheterizationchange in indexed cardiac output between baseline and after pulmonary vasodilatation
number of intimal lesions in small pulmonary arteriesbaseline at heart catheterizationnumber of intimal lesions in small pulmonary arteries

Countries

Netherlands

Contacts

Primary ContactFloris-Jan S Ridderbos, MD
f.j.s.ridderbos@umcg.nl+31503611506
Backup ContactElke S Hoendermis, MD PhD
e.s.hoendermis@umcg.nl+31503612359

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026